Rozanolixizumab, a new drug for generalized myasthenia gravis, has been designated as an orphan drug.

The Ministry of Food and Drug Safety recently announced that it designated UCB's gMG treatment Rozanolixizumab as an orphan drug. The target indication is the treatment of generalized myasthenia gravis in patients who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive and require additional therapy with corticosteroids or non-steroidal immunosuppressants. This drug was designated for expedited review by the U.S. FDA in January and is currently undergoing approval procedures in Japan. Rozanolixizumab is a type of monoclonal antibody for subcutaneous injection that t